This company listing is no longer active
Salud financiera de hoja de balance de Protalix BioTherapeutics
Salud financiera controles de criterios 0/6
Información clave
-264.9%
Ratio deuda-patrimonio
US$28.19m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$22.18m |
| Patrimonio | -US$10.64m |
| Total pasivo | US$66.43m |
| Activos totales | US$55.79m |
Actualizaciones recientes sobre salud financiera
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Pasivo a largo plazo: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historial y análisis de deuda-patrimonio
Nivel de deuda: PLX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducción de la deuda: PLX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: PLX has less than a year of cash runway based on its current free cash flow.
Pronóstico de cash runway: PLX has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.5% each year.